USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The inspections concluded with no Form 483 observations or significant critical findings
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Subscribe To Our Newsletter & Stay Updated